| VIATRIS |
VIATRIS |
92%
|
Under the terms of the Viatris Agreement, which included the delivery by the Company of a license to Viatris to develop and commercialize revefenacin, Viatris was responsible for reimbursement of the… |
| ACCORD-HEALTHCARE-INC |
ACCORD-HEALTHCARE-INC |
90%
|
As of February 28, 2026, the Company has settled all litigation with Accord Healthcare, Inc.; Cipla USA, Inc. and Cipla Limited; Eugia Pharma Specialties Ltd.; Lupin Pharmaceuticals, Inc.; Orbicular … |
| CIPLA-LIMITED |
CIPLA-LIMITED |
90%
|
As of February 28, 2026, the Company has settled all litigation with Accord Healthcare, Inc.; Cipla USA, Inc. and Cipla Limited; Eugia Pharma Specialties Ltd.; Lupin Pharmaceuticals, Inc.; Orbicular … |
| CIPLA-USA-INC |
CIPLA-USA-INC |
90%
|
As of February 28, 2026, the Company has settled all litigation with Accord Healthcare, Inc.; Cipla USA, Inc. and Cipla Limited; Eugia Pharma Specialties Ltd.; Lupin Pharmaceuticals, Inc.; Orbicular … |
| EUGIA-PHARMA-SPECIALTIES-LTD |
EUGIA-PHARMA-SPECIALTIES-LTD |
90%
|
As of February 28, 2026, the Company has settled all litigation with Accord Healthcare, Inc.; Cipla USA, Inc. and Cipla Limited; Eugia Pharma Specialties Ltd.; Lupin Pharmaceuticals, Inc.; Orbicular … |
| LUPIN-PHARMACEUTICALS-INC |
LUPIN-PHARMACEUTICALS-INC |
90%
|
As of February 28, 2026, the Company has settled all litigation with Accord Healthcare, Inc.; Cipla USA, Inc. and Cipla Limited; Eugia Pharma Specialties Ltd.; Lupin Pharmaceuticals, Inc.; Orbicular … |
| ORBICULAR-PHARMACEUTICAL-TECHNOLOGIES-PRIVATE-LI |
ORBICULAR-PHARMACEUTICAL-TECHNOLOGIES-PRIVATE-LI |
90%
|
As of February 28, 2026, the Company has settled all litigation with Accord Healthcare, Inc.; Cipla USA, Inc. and Cipla Limited; Eugia Pharma Specialties Ltd.; Lupin Pharmaceuticals, Inc.; Orbicular … |
| QILU-PHARMACEUTICALS-CO-LTD |
QILU-PHARMACEUTICALS-CO-LTD |
90%
|
As of February 28, 2026, the Company has settled all litigation with Accord Healthcare, Inc.; Cipla USA, Inc. and Cipla Limited; Eugia Pharma Specialties Ltd.; Lupin Pharmaceuticals, Inc.; Orbicular … |
| TEVA-PHARMACEUTICALS-INC |
TEVA-PHARMACEUTICALS-INC |
90%
|
As of February 28, 2026, the Company has settled all litigation with Accord Healthcare, Inc.; Cipla USA, Inc. and Cipla Limited; Eugia Pharma Specialties Ltd.; Lupin Pharmaceuticals, Inc.; Orbicular … |
| MANKIND-PHARMA-LTD |
MANKIND-PHARMA-LTD |
80%
|
The patent litigation against the one remaining generic company, Mankind Pharma Ltd., along with certain affiliates, remains pending. |
| GSK |
GSK plc |
72%
|
ditional clarity regarding any remaining value in ampreloxetine for our shareholders. There can be no assurance that any additional regulatory engagement will occur. Organizational Restructure Whil… |
| GSK |
GSK plc |
72%
|
Reciprocal relationship from GSK graph: Reciprocal relationship from TBPH graph: Reciprocal relationship from GSK graph: Reciprocal relationship from TBPH graph: Reciprocal relationship from GSK grap… |
| MRK |
Merck & Co., Inc. |
72%
|
payers may limit coverage to specific drug products on an approved list, or formulary, which might not include all of the FDA-approved drugs for a particular indication. Third-party payers are increa… |
| MRK |
Merck & Co., Inc. |
72%
|
Reciprocal relationship from MRK graph: Reciprocal relationship from TBPH graph: payers may limit coverage to specific drug products on an approved list, or formulary, which might not include all of … |
| ORANY |
ORANY |
72%
|
Reciprocal relationship from ORANY graph: Reciprocal relationship from TBPH graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from TBPH graph: and examining the medical necessi… |
| ORANY |
ORANY |
72%
|
and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. We may need to conduct expensive pharmacoeconomic studies in ord… |
| REGN |
Regeneron Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from REGN graph: Reciprocal relationship from TBPH graph: Reciprocal relationship from REGN graph: Reciprocal relationship from TBPH graph: Reciprocal relationship from REGN g… |
| REGN |
Regeneron Pharmaceuticals, Inc. |
72%
|
payers may limit coverage to specific drug products on an approved list, or formulary, which might not include all of the FDA-approved drugs for a particular indication. Third-party payers are increa… |
| SNYNF |
Sanofi |
72%
|
and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. We may need to conduct expensive pharmacoeconomic studies in ord… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from TBPH graph: and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their sa… |
| CAPITAL-RESOURCES |
CAPITAL-RESOURCES |
62%
|
s collaboration agreement $ 17,699 $ 15,388 $ 2,311 15 % We are entitled to a share of US profits and losses (65% to Viatris; 35% to Theravance Biopharma) received in connection with YUPELR… |
| REGENERON-PHARMACEUTICAL-INC |
REGENERON-PHARMACEUTICAL-INC |
62%
|
g our preclinical program for skin targeted, locally acting pan Janus kinase (JAK) inhibitors that can be rapidly metabolized as of October 2023. We have discontinued our JAK inhibitor research progr… |
| SIGNIFICANT-ACCOUNTING-POLICIES-THERAVANCE-BIOPH |
SIGNIFICANT-ACCOUNTING-POLICIES-THERAVANCE-BIOPH |
62%
|
— — — ( 13,579 ) ( 13,579 ) Balances at March 31, 2025 50,001 $ 1 $ 1,145,083 $ — $ ( 979,101 ) $ 165,983 See accompanying note… |
| THERAVANCE-BIOPHARMA-IRELAND-LIMITED |
THERAVANCE-BIOPHARMA-IRELAND-LIMITED |
62%
|
rietary nature of the intellectual property related to our technologies are not adequate, we may not be able to compete effectively in our current or future markets ” and “ Litigation to protect or d… |
| THERAVANCE-BIOPHARMA-R-D-INC |
THERAVANCE-BIOPHARMA-R-D-INC |
62%
|
rietary nature of the intellectual property related to our technologies are not adequate, we may not be able to compete effectively in our current or future markets ” and “ Litigation to protect or d… |
| THERAVANCE-RESPIRATORY-COMPANY-LLC |
THERAVANCE-RESPIRATORY-COMPANY-LLC |
62%
|
solidated statements of operations. The Company’s sublease income from its subleases is summarized below: Three Months Ended March 31, (In thousands) 2026 2025 Suble… |
